| Symbol | EPRX |
|---|---|
| Name | EUPRAXIA PHARMACEUTICALS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceuticals and Biotechnology |
| Address | 204 - 2590 CADBORO BAY ROAD, VICTORIA, British Columbia, Canada |
| Telephone | +1 250 590-3968 |
| Fax | — |
| — | |
| Website | https://www.eupraxiapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001581178 |
| Description | Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. Additional info from NASDAQ: |
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Read moreEupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Read moreEupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05608681 | A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). | Phase1 | Eosinophilic Esophagitis | Recruiting | 2023-03-31 | 2026-12-01 | ClinicalTrials.gov |
| NCT04120402 | Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoar… | Phase2 | Osteoarthritis, Knee | Completed | 2021-09-10 | 2023-06-01 | ClinicalTrials.gov |
| NCT02609126 | Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis | Phase1 | Osteoarthritis, Knee | Completed | 2016-04-01 | 2017-12-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle | Other | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT02609126 |
| EP-104IAR | Other | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT02609126 |
| Vehicle | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT04120402 |
| EP-104IAR 25 mg | Other | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT04120402 |
| Matching vehicle control | Other | Phase PHASE1 | Eosinophilic Esophagitis | RECRUITING | NCT05608681 |
| EP-104GI | Other | Phase PHASE1 | Eosinophilic Esophagitis | RECRUITING | NCT05608681 |
| Cyclobenzaprine Hydrochloride 10 MG | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04407377 |
| Tolperisone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04465266 |
| Placebo Oral Tablet | DRUG | Phase PHASE1 | Driving Impaired | COMPLETED | NCT03353922 |
| Cyclobenzaprine 10 Mg Oral Tablet | DRUG | Phase PHASE1 | Driving Impaired | COMPLETED | NCT03353922 |
| Placebo | OTHER | Phase PHASE1 | Healthy | COMPLETED | NCT04407377 |
| Tolperisone Hydrochloride | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04407377 |
| Matching vehicle control | OTHER | Phase PHASE1 | Eosinophilic Esophagitis | RECRUITING | NCT05608681 |
| EP-104GI | DRUG | Phase PHASE1 | Eosinophilic Esophagitis | RECRUITING | NCT05608681 |
| EP-104IAR 25 mg | DRUG | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT04120402 |
| Vehicle | DRUG | Phase PHASE2 | Osteoarthritis, Knee | COMPLETED | NCT04120402 |
| EP-104IAR | DRUG | Phase PHASE1 | Osteoarthritis, Knee | COMPLETED | NCT02609126 |